EGFR and non-small cell lung carcinoma: These results suggest that EGFR-TKI-resistant mutations evolved differently in the extracranial lesion and LM from the same patient, providing further evidence that extracranial and LM lesions progress independently and supporting the notion that both CSF cfDNA and plasma cfDNA are necessary for comprehensive genetic profiling to make clinical decisions for NSCLC patients with LM.